目的 探討菊明降壓丸聯(lián)合替米沙坦片治療原發(fā)性高血壓的臨床療效。方法 選擇2020年2月-2020年7月在河南科技大學(xué)第一附屬醫(yī)院治療的96例原發(fā)性高血壓患者，根據(jù)入院順序分為對(duì)照組（48例）和治療組（48例）。對(duì)照組口服替米沙坦片，40 mg/次，血壓控制不理想可增至80 mg/次，1次/d；治療組在對(duì)照組的基礎(chǔ)上口服菊明降壓丸，6 g/次，3次/d。兩組患者治療4周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者血壓水平、臨床癥狀消失時(shí)間，血清同型半胱氨酸（Hcy）、血管緊張素Ⅱ（AngⅡ）、胰島素樣生長(zhǎng)因子-1（IGF-1）、可溶性凝集素樣氧化低密度脂蛋白受體1（sLOX-1）、單核細(xì)胞趨化蛋白-1（MCP-1）和血管緊張素轉(zhuǎn)化酶（ACE）水平及血管內(nèi)皮功能。結(jié)果 治療后，對(duì)照組臨床有效率為81.25%，顯著低于治療組的97.92%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者收縮壓（SBP）、舒張壓（DBP）均下降（P<0.05），并且治療組血壓水平明顯好于對(duì)照組（P<0.05）。治療后，治療組癥狀消失時(shí)間明顯早于對(duì)照組（P<0.05）。治療后，兩組患者血清Hcy、AngⅡ、IGF-1、sLOX-1、MCP-1、ACE水平均下降（P<0.05），且治療組患者降低更顯著（P<0.05）。治療后，兩組患者肱動(dòng)脈內(nèi)皮依賴(lài)性舒張功能（EDD）、肱動(dòng)脈非內(nèi)皮依賴(lài)的舒張功能（NMD）均顯著升高（P<0.05），且治療組患者升高更明顯（P<0.05）。結(jié)論 菊明降壓丸聯(lián)合替米沙坦片治療原發(fā)性高血壓患者可有效改善患者臨床癥狀，降低機(jī)體細(xì)胞因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Juming Jiangya Pills combined with telmisartan in treatment of essential hypertension. Methods Patients (96 cases) with essential hypertension in the First Affiliated Hospital of Henan University of Science and Technology from February 2020 to July 2020 were divided into control (48 cases) and treatment (48 cases) groups based on visiting sequence. Patients in the control group were po administered with Telmisartan Tablets, 40 mg/time, and increased to 80 mg/time under unsatisfactory control of blood pressure, once daily. Patients in the treatment group were po administered with Juming Jiangya Pills on the basis of the control group, 6 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the blood pressure, the disappearance time of clinical symptoms, and the serum levels of Hcy, AngⅡ, IGF-1, sLOX-1, MCP-1 and ACE, and the vascular endothelial function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.25%, which was significantly lower than 97.92% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the SBP and DBP in two groups were significantly decreased (P<0.05), and the blood pressure in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the disappearance time of clinical symptoms in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the serum levels of Hcy, AngⅡ, IGF-1, sLOX-1, MCP-1, and ACE in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the EDD and NMD levels in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Juming Jiangya Pills combined with telmisartan can effectively improve the clinical symptoms in treatment of essential hypertension, reduce the level of cytokines, which has a certain clinical application value.

R972